Aicuris Gmbh + Co. Kg.

Bayer Aktiengesellschaft

Tobias Schlapp

Olaf Weber

Angela Siegling

Hans-Dieter Volk

Andrew Allan Mercer

Stephen Bruce Fleming

Andreas Knorr

Claudia Hirth-Dietrich

Sonja Maria Tennagels

Gudrun Theiss

Sonja Maria Friederichs

Sonja-Maria Friederichs

The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins, and to the use of said recombinant proteins or fragments for the preparation of pharmaceutical compositions.

Recombinant proteins of parapdxvirus ovis and pharmaceutical compositions therefrom

[object Object]

Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom

The present invention relates to the use of strains of Parapoxvirus ovis as immunotherapeutic agents for immunodeficiencies of an infectious or non-infectious nature, and to the use of strains of Parapoxvirus ovis for treating tumor diseases and viral infections, and diseases which accompany them, and the use of strains of Parapoxvirus ovis for producing medicaments for use in humans and animals.

Methods of treating viral infections

The present invention relates to the use, in humans, of inactivated parapoxviruses for the prophylaxis and treatment of diseases which are accompanied by an increased deposition of collagen, with it being possible for both internal organs, such as the liver, and the skin and its appended structures, to be affected. The invention relates, in particular, to liver fibrosis and/or liver cirrhosis consequent upon virus hepatitis, or to ethanol-induced liver diseases and to cystic fibrosis.

Use of strains of parapoxvirus ovis against organ fibrosis

Growing community of inventors

Goch, Germany

Tobias Schlapp